Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules

Kepal N. Patel, Trevor E. Angell, Joshua Babiarz, Neil M. Barth, Thomas Blevins, Quan Yang Duh, Ronald A. Ghossein, R. Mack Harrell, Jing Huang, Giulia C. Kennedy, Su Yeon Kim, Richard T. Kloos, Virginia A. Li Volsi, Gregory W. Randolph, Peter M. Sadow, Michael H. Shanik, Julie A. Sosa, S. Thomas Traweek, P. Sean Walsh, Duncan WhitneyMichael W. Yeh, Paul W. Ladenson

Research output: Contribution to journalArticlepeer-review

Abstract

IMPORTANCE Use of next-generation sequencing of RNA and machine learning algorithms can classify the risk of malignancy in cytologically indeterminate thyroid nodules to limit unnecessary diagnostic surgery. OBJECTIVE To measure the performance of a genomic sequencing classifier for cytologically indeterminate thyroid nodules. DESIGN, SETTING, AND PARTICIPANTS A blinded validation study was conducted on a set of cytologically indeterminate thyroid nodules collected by fine-needle aspiration biopsy between June 2009 and December 2010 from 49 academic and community centers in the United States. All patients underwent surgery without genomic information and were assigned a histopathology diagnosis by an expert panel blinded to all genomic information. There were 210 potentially eligible thyroid biopsy samples with Bethesda III or IV indeterminate cytopathology that constituted a cohort previously used to validate the gene expression classifier. Of these, 191 samples (91.0%) had adequate residual RNA for validation of the genomic sequencing classifier. Algorithm development and independent validation occurred between August 2016 and May 2017. EXPOSURES Thyroid nodule surgical histopathology diagnosis by an expert panel blinded to all genomic data. MAIN OUTCOMES AND MEASURES The primary end point was measurement of genomic sequencing classifier sensitivity, specificity, and negative and positive predictive values in biopsies from Bethesda III and IV nodules. The secondary end point was measurement of classifier performance in biopsies from Bethesda II, V, and VI nodules. RESULTS Of the 183 included patients, 142 (77.6%) were women, and the mean (range) age was 51.7 (22.0-85.0) years. The genomic sequencing classifier had a sensitivity of 91% (95% CI, 79-98) and a specificity of 68% (95% CI, 60-76). At 24% cancer prevalence, the negative predictive value was 96% (95% CI, 90-99) and the positive predictive value was 47% (95% CI, 36-58). CONCLUSIONS AND RELEVANCE The genomic sequencing classifier demonstrates high sensitivity and accuracy for identifying benign nodules. Its 36% increase in specificity compared with the gene expression classifier potentially increases the number of patients with benign nodules who can safely avoid unnecessary diagnostic surgery.

Original languageEnglish (US)
Pages (from-to)817-824
Number of pages8
JournalJAMA surgery
Volume153
Issue number9
DOIs
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules'. Together they form a unique fingerprint.

Cite this